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programming language, using a 3-dimensional transition
matrix, where the third dimension represents time spent
in the current state. The ability of R to manipulate n-
dimensional numeric arrays allowed the complex model
to be easily implemented. RESULTS: The use of a semi-
Markov process to model cost-effectiveness in epilepsy
allowed the reported natural history of the condition to
be accurately reﬂected. This was achieved efﬁciently and
transparently using the R statistical programming lan-
guage. Furthermore, the alternative (and commonly 
used) assumption of ﬁxed transition probabilities with
respect to time generated important differences in cost-
effectiveness results compared to the semi-Markov
process. CONCLUSIONS: Semi-Markov process models
may be useful in modeling a wide range of treatment
processes. By adding further dimensions to the transition
matrix, the transition probabilities could be made depen-
dant on other aspects of patients’ history providing a
useful alternative to discrete event simulation, where
increased speed of execution will aid probabilistic mod-
eling.
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OF TREATMENTS FOR RHEUMATOID
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OBJECTIVES: To compare the analytic judgements, data
and assumptions of different models used in the economic
evaluation of inﬂiximab, one of a new class of drugs for
rheumatoid arthritis (RA). The purpose was to under-
stand why different models give such varying results.
METHODS: A detailed assessment was made of three
models, one submitted (in a reimbursement dossier) by
the manufacturer, one produced by an independent aca-
demic group and one published in the literature. Factors
considered included the key data inputs, assumptions
about the sequencing of treatments for RA, the estima-
tion of cost offsets and the modelling of the maintenance
of treatment effect for patients continuing or discontinu-
ing inﬂiximab. RESULTS: Two of the models, although
embodying different methodological approaches, gave
fairly similar results (approximately £30,000–£40,000
cost per additional quality-adjusted life-year gained). The
third model, by the independent academic group, gave
much higher estimates, around £100,000 per QALY. The
differences were mainly because of the assumptions about
the positioning of inﬂiximab in the treatment sequence
and assumptions about the long-term effect of therapy.
CONCLUSIONS: Economic models of treatments for
rheumatoid arthritis incorporate several key analytic
judgements, which can have major impacts on cost-effec-
tiveness. Two of the three models examined gave similar
results, which suggests that consensus can be reached on
several of the main methodological issues.
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OBJECTIVES: Decision analytic models relate health
outcomes in a speciﬁc health state with the costs arisen
in this health state. In most of the decision analytic
models we will ﬁnd the option that people will die either
due to a speciﬁc disease or due to other unspeciﬁed
causes. Treatment costs in the last two years before dying
are exceptionally high. Applying the health state costs to
a patient who is dying will underestimate the true costs.
Additional costs should be applied to correct for this
potential bias. This will present a methodological and
pragmatical approach to estimate costs due to dying 
of a disease speciﬁc cause and unspeciﬁed causes.
METHODS: Age-speciﬁc and non age-speciﬁc costs were
calculated. Dying of unspeciﬁed causes revealed to the
most common causes for dying reﬂecting a background
mortality. To assess the disease speciﬁc costs of dying—
in our case for hepatitis C virus associated diseases; rele-
vant causes of dying have been identiﬁed. Principle of all
cost calculations was the combination of length of termi-
nal hospital stay multiplied by per diem costs. RESULTS:
Over the age of 15 years costs of dying are similar for
disease-speciﬁc causes and unspeciﬁed causes with a range
between €2.133 and €3.701. In the age group between 0
and 4 years costs for unspeciﬁed causes are about €7.645,
in the age group between 5 and 14 years costs are €8.011.
Hepatitis C Virus associated costs for both age groups are
€19.987, respectively €13.018. CONCLUSIONS: The
described pragmatical approach just considers additional
costs in consequence of the last inpatient treatment before
death. Therefore costs are still underestimated. Main
advantage of the described approach will be the applica-
bility to different decision analytic models.
METHODOLOGICAL ISSUES—Other Studies
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OBJECTIVES: The purpose of this study was to deter-
mine whether short courses offered by ISPOR at its
Annual Meeting are a cost-effective means of education
and enhancing meeting attendance, or if the type, com-
plexity, number, or duration of the courses should be
changed. METHOD: Four different survey techniques
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were used. Participants were surveyed about: a) effec-
tiveness of individual courses and instructors; b) conve-
nience of courses being offered at the Annual Meeting; c)
pros and cons of the courses; and d) the numbers and
hours taken by participants in different sub-populations.
A break-even analysis was done to determine the number
of participants who need to attend a course before ISPOR
can recover its ﬁxed costs. RESULTS: Three hundred one
people (12% non-members, 11% non-USA based) took
538 courses at the Annual Meeting, and the response rate
to the survey was 58%. New courses and suggestions
were offered for improving the quality. A break-even
analysis determined that 17 people were needed for new
courses. The average number and duration of courses was
1.79 and 8.7 hours respectively. There was no difference
in results between members and non-members, or
between USA and non-USA participants, but hours dif-
fered signiﬁcantly based on participant setting. The
courses were considered useful by 95% and recom-
mended by 91% of respondents. CONCLUSIONS:
Strong interest in adding new courses and increasing the
complexity of existing courses shows that opportunities
exist for expansion by adding courses and increasing the
number of 8 hour courses. Speciﬁc marketing plans
should be developed to increase the average number of
courses/hours taken by attendees. Live courses should
continue to be offered in conjunction with the Annual
Meeting to promote ISPOR membership and attendance
at the Annual Meeting. Existing course instructors should
continue to add more cases, workshop sessions, and
involve the participants in active learning.
METHODOLOGICAL ISSUES—Quality of Life
Studies
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REGULATORS FOR THE CROSS-CULTURAL
ADAPTATION OF PRO MEASURES
Conway K, Mear I, Acquadro C
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Introduction With the growing use of Patient-Reported
Outcomes (PROs) questionnaires for the evaluation of
medicines in Europe, the need for international measures
has increased. In response to European regulators’ con-
cerns about the methodology used to achieve cultural
adaptation of PRO measures, the ERIQA Group and
Mapi Research Institute have investigated current guide-
lines. OBJECTIVES: To identify and review the methods
used for cultural adaptation of PRO measures, to propose
recommendations of best practice to European regulators.
METHODS: Relevant papers were identiﬁed from
Medline, Embase, and Mapi Research Institute’s data-
base. The databases were explored with “quality of life”,
“questionnaires”, “health status indicators” matched
with “translating”, “cross-cultural comparison”, “trans-
lations issues” and “cross-cultural research”. Papers pub-
lished between January 1966 and April 2001 were con-
sidered. 415 abstracts were reviewed. Papers were
included if they proposed guidelines or recommendations
and/or they reviewed and criticised methods. RESULTS:
Thirty-two papers met the inclusion criteria. We identi-
ﬁed 14 sets of guidelines. The review highlighted a lack
of consensus regarding the terminology to qualify the
process of adapting a PRO measure from a source to a
target language, and the scope covered by this terminol-
ogy. Common points included multiple forward trans-
lations, reconciliation sessions, some form of
back-translations and psychometric validation. Differ-
ences were seen in the importance given to back-
translation, focus groups, cognitive debrieﬁng, and
recruitment criteria for translators. With only two arti-
cles comparing methodologies, the review could not
determine the best method to apply among the 14 iden-
tiﬁed. CONCLUSION: This review demonstrates dis-
parity in deﬁnitions and methods. There is no evidence
proving that one method leads to better results than
another. We propose providing regulators with an
overview of what most investigators recommend as
minimum requirements. This proposal will be presented
in the form of a checklist including a maximum of 12
steps from concept deﬁnition to psychometric evaluation,
depending on the target culture and/or language and type
of PRO.
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OBJECTIVE: To evaluate the vision-related quality of life
(QoL) consequences of the best and the worst eye, respec-
tively, in patients suffering from age related macular
degeneration (AMD). METHODS: One hundred four-
teen patients with a diagnosis of exudative AMD and a
primary or recurrent subfoveal neovascular membrane
(<5400mm in its greater dimension; >50% choroidal neo-
vascularization representing >1mm2) were included.
ETDRS visual acuity (VA in LogMAR) was measured in
both eyes separately. Vision-related QoL was assessed
using the NEI-VFQ-39 (13 scores from 0 to 100). An
analysis of variance was performed on the QoL scores,
including best eye (VA > 0.3), worst eye (VA > 1), and
their interaction. RESULTS: Best eye VA was 0.34 on
average and 43.0% had a VA > 0.3. Worst eye VA was
0.85 on average and 32.5% had a VA > 1. VA was not
linked to general health and ocular pain scores. General
vision, near activities, distance vision, driving, mental
health, role difﬁculties, dependency, peripheral vision 
and the global scores were affected both by best eye VA
